Our People

Meet Our Team

Dr John Goodfellow

BM BCh, MRCP(UK), MRCP(Neurology),

Chief Executive Officer

John Goodfellow has 20 years of combined experience in biomedical research and clinical practice. With a background in basic laboratory neuroscience he has worked in the field of neuroimmunology since 2002 and has had extensive practice in antibody production, purification and identification techniques in addition to diagnostic laboratory medicine and clinical neurology and neuroimmunology. John has been involved in multiple clinical trials investigating immunomodulatory agents for various autoimmune neurological conditions.

He studied medicine at the University of Oxford, holds a PhD in Clinical Neuroscience and is currently a Clinical Lecturer in Neurology at the University of Glasgow and Deputy Clinical Director of the Neuroimmunology Laboratory, Queen Elizabeth University Hospital, Glasgow, United Kingdom.

Eric Wagner

Chief Scientific Officer

Eric Wagner is Chief Scientific Officer of Abaxon and also the founder of The Antibody Company. Having established hybridoma cell lines and working with monoclonal antibodies for over 20 years in both academic and corporate environments, he brings a wealth of invaluable experience to Abaxon.

Eric has spent 10 years working in a CRO dealing closely with clients and managing their projects. Consequently he has a deep understanding of the critical need for high quality products, precise timelines, and the importance of excellent communication during projects.

Dr Jonathan H. Dempsey


Member of the Board of Directors

Jon Dempsey is an expert in the discovery and development of biopharmaceuticals, specifically monoclonal antibodies, and in manufacturing and technology transfer of cell based processes. He has spent nearly 30 years working with biological molecules expressed in living organisms. He holds a PhD in Industrial Biotechnology from the University of Edinburgh where he studied the impact of industrial environments on antibody secreting cells.

Jon worked at Celltech (now Lonza Biologics) where he was part of the team which commercialised the first gene-activated biopharmaceutical and transferred this to manufacturing. He also designed novel processes for expressing proteins and again took these to manufacturing.

In 1998, he was one of the founding members of the Development team at Cambridge Antibody Technology, building the Upstream Process Team. Cambridge Antibody Technology was the inventor of in vitro human antibody libraries and with this company he took over ten molecules from this library into the clinic.

Having spent almost ten years at Cambridge Antibody Technology Jon joined Invitrogen to form a group commoditising technologies applicable to therapeutic protein development. They developed the world’s first commercially available cell line development kit and built complete workflows for early stage customers. He was the technical and commercial face of Invitrogen’s industrial business in the EU and India converting over twenty European and Indian companies to use their technology to develop therapies.

Jon has experience in transfering antibody processes globally, supporting products from discovery to the clinic. His teams have designed, commissioned and built development laboratories, setup pilot manufacturing facilities, and developed the expression technology still used today.

Jon is also the Managing Director of Dempsey Consulting and a founding Partner of Pathway Biopharma.

Vishal Jain

Member of the Board of Directors

Mr. Jain has over a decade of investment banking experience in the healthcare sector, including biotech, pharma, medical devices and diagnostics sectors. Prior to that he spent many years in strategic and operations consulting in multiple industries.
Over the course of his career, he has led multiple public offerings for equity and debt, and has provided strategic advice to large as well as small corporations, with respect to mergers, acquisitions, divestitures, and spin-offs.
Mr. Jain has executed over $100 billion of transactions, including M&A, equity and debt offerings.
He has worked at some of the largest global banks including Mizuho and UBS.
Mr. Jain obtained his Bachelors in Electronics Engineering at National Institute of Technology, India and MBA at Cornell University, NY.

Dr Govind Chavada


Member of the Board of Directors

An entrepreneur and practicing physician, Govind’s mission is to transform the healthcare industry by creating an integrated platform for clinicians, scientists and the pharmaceutical industry. He identifies and invests in companies that change medicine by bringing novel drugs, technologies and devices to market. Govind has the medical background to create value for companies from the earliest stage through to clinical trials and regulatory approval. He began his career as a practising Neurologist with a special interest in inflammatory neurological conditions. Govind earned his medical degree from the Baroda Medical college and has a research degree in neuroimmunology from the University of Glasgow.

Dr Dheeeaj Kalladka

Scientific Advisory Panel

Dheeraj is a practising vascular neurologist with a special interest in therapeutics and regenerative approaches. He has experience of being involved in several aspects of clinical trials including clinical academic research in the use of stem cells in stroke.

His passion to evaluate academic research to guide development of therapeutics and bring cost effective solutions to clinical practice is an invaluable asset as scientific advisor to Abaxon. He is an associate member of American Academy of Neurology, Fellow of the European Stroke Organisation and member of the Association of British Neurologists and British Medical Association.